Nuclear Medicine: Page 22

Navidea secures Indian regulatory approval for Lymphoseek

By AuntMinnie.com staff writers

Navidea Biopharmaceuticals has secured regulatory approval from India's Central Drugs Standard Control Organization for its technetium-99m tilmanocept radiopharmaceutical Lymphoseek.

April 17, 2022

Shine appoints two new board members

By AuntMinnie.com staff writers

Medical isotope company Shine Technologies has appointed Holli Ladhani and Janet Wong to the company's board of directors.

April 13, 2022

ITM, MTTI ink lutetium-177 supply deal

By AuntMinnie.com staff writers

ITM Isotope Technologies Munich's subsidiary ITM Medical Isotopes and biopharmaceutical company Molecular Targeting Technologies (MTTI) have signed a supply deal for no-carrier-added lutetium-177.

April 12, 2022

NYSE accepts Navidea bid to comply with stock listing rules

By AuntMinnie.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals said the New York Stock Exchange (NYSE) has accepted its plan to regain compliance with the stock exchange's listing requirements. Navidea now has until July 28, 2023, to regain compliance.

April 12, 2022

Radionetics Oncology taps de Silva as CEO

By AuntMinnie.com staff writers

Pharmaceutical firm Radionetics Oncology has named Dr. Nishan de Silva as CEO and a director of the company's board. De Silva most recently was with AFYX Therapeutics.

April 11, 2022

FDA clears clinical trial for Blue Earth radiopharmaceutical

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has given the go-ahead to Blue Earth Therapeutics to conduct a clinical study of its radiopharmaceutical labeled with lutetium-177 for treatment of metastatic, castrate-resistant prostate cancer.

April 11, 2022

German scientists develop method for less uranium waste

By AuntMinnie.com staff writers

Technical University of Munich scientists have developed a new processing method for molybdenum-99 (Mo-99) that results in significantly less waste from low-enriched uranium targets.

March 30, 2022

DMS Health lands Vizient mobile imaging contract

By AuntMinnie.com staff writers

DMS Health Technologies has secured a mobile imaging supply contract with group purchasing organization Vizient.

March 28, 2022

GE announces first patient dosed with new PET radiopharmaceutical

By AuntMinnie.com staff writers

GE Healthcare announced that the first patient has been dosed in a phase III trial underway in France with a new dopamine transporter PET imaging radiopharmaceutical.

March 27, 2022

ITM promotes supply deal with Novartis for Pluvicto

By AuntMinnie.com staff writers

German radiopharmaceutical firm ITM Isotope Technologies Munich SE (ITM) highlighted its lutetium-177 supply deal with Novartis in the wake of the U.S. Food and Drug Administration's approval of the company's Pluvicto radioligand therapy.

March 24, 2022

Clarity launching trial for prostate cancer therapy

By AuntMinnie.com staff writers

Clarity Pharmaceuticals is launching an investigator-initiated trial that will focus on the use of its copper-64 (Cu-64)-labeled radiopharmaceutical, Cu-64 SAR-bisPSMA, in prostate cancer.

March 23, 2022

FDA approves Lu-177 PSMA-617 for prostate cancer treatment

By Will Morton

The U.S. Food and Drug Administration (FDA) has approved lutetium-177 (Lu-177) prostate-specific membrane antigen radioligand therapy for the treatment of patients with metastatic prostate cancer.

March 22, 2022

Previous Page

Page 22 of 438

Next Page